Precigen Actobio

Foundation date

03/07/2006

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.

We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.

Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.

Upcoming events

Latest news

  • argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • Galapagos appoints Simon Sturge to its Board of Directors

    Tuesday September 19th 2023

  • 13th Investment for HERAN Partners: Broken String Biosciences (UK)

    Tuesday September 19th 2023